Cardioactivity and solid-state structure of two 4-isoxazolyldihydropyridines related to the 4-aryldihydropyridine calcium-channel blockers
作者:John I. McKenna、Ludwig Schlicksupp、Nicholas R. Natale、Roger D. Willett、Bruce E. Maryanoff、Stephen F. Flaim
DOI:10.1021/jm00397a035
日期:1988.2
Diethyl 2,6-dimethyl-4-(5-ethyl-3-phenylisoxazol-4-yl)-1,4-dihydroyprid ine-3,5- dicarboxylate (5) and diethyl 2,6-dimethyl-4-(5-isopropyl-3-phenylisoxazol-4-yl)-1,4-dihydropyri dine-3,5- dicarboxylate (6) were synthesized, and their molecular structures were determined by X-ray crystallography. In compound 5, which has an ethyl group at the C5 position of the isoxazole ring, the deviation from planarity
2,6-二甲基-4-(5-乙基-3-苯基异恶唑-4-基)-1,4-二氢吡啶-3,5-二羧酸二乙酯(5)和2,6-二甲基-4-乙基二乙酯合成了(-异丙基-3-苯基异恶唑-4-基)-1,4-二氢吡啶-3,5-二羧酸酯(6),并通过X射线晶体学测定了它们的分子结构。在异恶唑环的C5位置具有乙基的化合物5中,二氢吡啶(DHP)环的平面度偏差是所有已知DHP衍生物中最小的。在这两种化合物中,芳香环(异恶唑)与DHP环之间的二面角(在相似的具有生物活性的二氢吡啶中约为90度)略小(分别为82.7度和85.2度)。在这两种化合物中,一个酯基与DHP环共面,而另一个则与DHP环偏离14个平面。7度(乙基)和18.8度(异丙基)。在Langendorff分析中,发现5和6均为血管扩张药。6对心脏血流的功效与硝苯地平相似。但是,5的衰减很大。由于异恶唑基类似物6缺乏与硝苯地平相关的显着负性变力活性,因此6作为抗高血压药或抗心绞痛药具有希望。